» Articles » PMID: 39416602

Efficacy and Safety of Refined Nursing Combined with Zhao's Thunder-Fire Moxibustion in Treating Patients with Gastric Cancer of Spleen-Qi Deficiency Syndrome: A Clinical Study

Overview
Journal Pak J Med Sci
Specialty General Medicine
Date 2024 Oct 17
PMID 39416602
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the efficacy and safety of refined nursing combined with Zhao's thunder-fire moxibustion in treating patients with gastric cancer (GC) of spleen-Qi deficiency syndrome.

Methods: This was a retrospective study. Ninety patients with GC of spleen-Qi deficiency syndrome admitted to Baoding Hospital of Traditional Chinese Medicine from February 2022 to March 2023 were randomly divided into the observation group and the control group. Patients in the control group were intervened with XELOX chemotherapeutic regimen + routine nursing. On this basis, patients in the observation group were additionally treated with refined nursing combined with Zhao's thunder-fire moxibustion. Changes in Traditional Chinese Medicine (TCM) syndrome scores, KPS scores for physical status, and quality of life (QOL) scores were observed and compared between the two groups before and after treatment.

Results: After treatment, the scores of anorexia, fatigue and weakness, postprandial abdominal bloating, loose stools, mental fatigue and laziness to speak decreased significantly in the two groups (< 0.05), and each TCM syndrome score in the observation group was significantly lower than that in the control group (< 0.05). After treatment, KPS and QOL scores in the observation group were significantly higher than those in the control group (< 0.05). The overall nursing satisfaction was 93.3% (42/45) in the observation group, which was significantly higher than 71.1% (32/45) in the control group (< 0.05).

Conclusion: Refined nursing combined with Zhao's thunder-fire moxibustion can alleviate the clinical symptoms of patients with GC of spleen-Qi deficiency syndrome, reduce chemotherapeutic-induced adverse reactions, with high clinical application value.

References
1.
Li S, Yu W, Xie F, Luo H, Liu Z, Lv W . Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nat Commun. 2023; 14(1):8. PMC: 9810618. DOI: 10.1038/s41467-022-35431-x. View

2.
Tan Z . Recent Advances in the Surgical Treatment of Advanced Gastric Cancer: A Review. Med Sci Monit. 2019; 25:3537-3541. PMC: 6528544. DOI: 10.12659/MSM.916475. View

3.
Torphy R, Fujiwara Y, Schulick R . Pancreatic cancer treatment: better, but a long way to go. Surg Today. 2020; 50(10):1117-1125. PMC: 7837389. DOI: 10.1007/s00595-020-02028-0. View

4.
Chen Y, Chen Y, Wang Z, Li H, Wang Y . Clinical value of propranolol combined with oxaliplatin and tigio in concurrent chemoradiotherapy for locally advanced gastric cancer. Pak J Med Sci. 2022; 38(5):1316-1320. PMC: 9247783. DOI: 10.12669/pjms.38.5.5311. View

5.
Bao C, Wang C, Li G, Yan Y, Wang D, Jin X . Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome. World J Gastroenterol. 2019; 25(32):4696-4714. PMC: 6718040. DOI: 10.3748/wjg.v25.i32.4696. View